2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P2061
    Leualacin 128140-12-5 98%
    Leualacin, a calcium channel blocker, can be isolated from the fungus Hapsidospora irregularis.
    Leualacin
  • HY-P2072
    GF109 79873-93-1 98%
    GF109 is a potent parenteral inhibitor of angiotensin converting enzyme (ACE). GF109 has antihypertensive effects.
    GF109
  • HY-P2595
    SKF 103784 111372-60-2 98%
    SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction.
    SKF 103784
  • HY-P3082
    SKF 106760 126053-71-2 98%
    SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis.
    SKF 106760
  • HY-P4551
    Hippuryl-His-Leu-OH 31373-65-6 98%
    Hippuryl-His-Leu-OH (N-Benzoyl-Gly-His-Leu) is a substrate for detecting the activity of angiotensin I converting enzyme. The His-Leu released by Hippuryl-His-Leu-OH can react with o-phtbaldialdehyde or Fluorescamine (HY-D0715) for fluorescence detection.
    Hippuryl-His-Leu-OH
  • HY-Z3151
    3'-(2-Fluorophenyl) ezetimibe 1798008-25-9 98%
    3'-(2-Fluorophenyl) ezetimibe is an isomer of the cholesterol transport inhibitor Ezetimibe (HY-17376).
    3'-(2-Fluorophenyl) ezetimibe
  • HY-Z6544
    N-(2,6-dimethylphenyl)-2-(ethyl(methyl)amino)acetamide hydrochloride 50295-20-0 98%
    N-(2,6-dimethylphenyl)-2-(ethyl(methyl)amino)acetamide hydrochloride is an impurity in the sodium channel inhibitor Lidocaine (HY-B0185).
    N-(2,6-dimethylphenyl)-2-(ethyl(methyl)amino)acetamide hydrochloride
  • HY-Z8381
    Ramipril diketopiperazine 108731-95-9 98%
    Ramipril diketopiperazine is an impurity in the ACE inhibitor Ramipril (HY-B0279).
    Ramipril diketopiperazine
  • HY-100145
    Prifuroline 70833-07-7 98%
    Prifuroline is an antiarrhythmic agent.
    Prifuroline
  • HY-10064R
    Ticagrelor (Standard) 274693-27-5
    Ticagrelor (Standard) is the analytical standard of Ticagrelor. This product is intended for research and analytical applications. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
    Ticagrelor (Standard)
  • HY-100993
    α-Methylserotonin maleate 97469-12-0 98%
    α-Methylserotonin maleate is a potent and selective agonist of 5-HT2 receptor. α-Methylserotonin maleate is an analogue of serotonin formed in vivo from α-Methyltryptophan. α-Methylserotonin maleate mediates the lymphatic smooth muscle contraction and prevents the up-regulation of serotonin-receptor-mediated phosphoinositide hydrolysis.
    α-Methylserotonin maleate
  • HY-10119R
    Vorapaxar (Standard) 618385-01-6
    Vorapaxar (Standard) is the analytical standard of Vorapaxar. This product is intended for research and analytical applications. Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner.
    Vorapaxar (Standard)
  • HY-101574
    Pratosartan 153804-05-8 98%
    Pratosartan is a selective angiotensin II receptor antagonist.
    Pratosartan
  • HY-101577
    NCX899 690655-41-5 98%
    NCX899 is a NO-releasing derivative of enalapril, and shows inhibitory activity against angiotensin-converting enzyme (ACE) activity.
    NCX899
  • HY-101594
    Tulopafant 116289-53-3 98%
    Tulopafant is a platelet activating factor (PAF) antagonist.
    Tulopafant
  • HY-101598
    PD-159020 177904-00-6 98%
    PD-159020 is a non-selective ETA/ETB antagonist, with IC50s of 30 and 50 nM for hETA and hETB, respectively.
    PD-159020
  • HY-101610
    OPC-28326 167626-17-7 98%
    OPC-28326 is a selective peripheral vasodilator and an angatonist of α2-adrenergic receptor, with Ki of 2040, 285, and 55 nM for α2A-, α2B- and α2C-adrenoceptors, respectively.
    OPC-28326
  • HY-101617
    Droxicainide 78289-26-6 98%
    Droxicainide is an antiarrhythmic agent.
    Droxicainide
  • HY-101618
    L162389 169281-53-2 98%
    L162389 is a potent antagonist of angiotensin AT1 receptor with Ki of 28 nM.
    L162389
  • HY-101661
    Win 58237 158001-76-4 98%
    Win 58237 is a cyclic nucleotide phosphodiesterase (PDE) inhibitor, with Ki of 170 nM for PDE V, possessing vasorelaxant activity.
    Win 58237
Cat. No. Product Name / Synonyms Application Reactivity